NCT06293755

Brief Summary

The purpose of this study is to assess the efficacy and safety of microneedle patch with botulinum toxin for improving enlarged pores.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
16

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Feb 2024

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 28, 2024

Completed
Same day until next milestone

Study Start

First participant enrolled

February 28, 2024

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 5, 2024

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 5, 2024

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 25, 2024

Completed
Last Updated

March 5, 2024

Status Verified

February 1, 2024

Enrollment Period

6 days

First QC Date

February 28, 2024

Last Update Submit

February 28, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change from baseline of enlarged pores as measured by VISIA (pores parameter) and using pore score

    the used pore scores, patients with visible pores took the score "1," and those with enlarged pores took "2." When black heads were embedded on facial pores the score was "3." The scores were assessed by 2 investigators who were blinded to the treatment used on each side.

    Post-intervention, week 4 and week 16

Study Arms (2)

Microneedle patch with Botulinum toxin

EXPERIMENTAL

Participants recieve microneedle path with 20 units Botulinum toxin at nose and cheek one side.

Device: Microneedle patch

Intradermal Botulinum toxin injection

ACTIVE COMPARATOR

Participants recieve intradermal 20 units Botulinum toxin injection at nose and cheek in other side.

Device: Intradermal injection

Interventions

with 20 units botulinum toxin

Microneedle patch with Botulinum toxin

with 20 units botulinum toxin

Intradermal Botulinum toxin injection

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • At least 18 years old and concerned about enlarged pores
  • Have pore size 0.3-0.6 mm
  • Have pore parameter in each other side of faces not different more than 5%

You may not qualify if:

  • Any neuromuscular condition
  • Pregnancy or breast feeding
  • History of allergy : Botulinum toxin, topical anesthesia
  • History of keloid or hypertrophic scar
  • History of coagulation or receiving medication that causes coagulation disorder
  • Using drugs that have interaction with Botulinum toxin
  • Using topical medication that improves enlarged pores in 1 month
  • Taking medication that improves enlarged pores in 1 month
  • Receiving the laser/treatment/chemical peeling in 6 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dhurakij Pundit University

Lak Si, Bangkok, Thailand

Location

Related Publications (1)

  • Salem RM, Salah SAE, Ibrahim SE. Microbotox injection versus its topical application following microneedling in the treatment of wide facial pores: A split face comparative study. J Cosmet Dermatol. 2023 Apr;22(4):1249-1255. doi: 10.1111/jocd.15590. Epub 2023 Jan 6.

MeSH Terms

Interventions

Injections, Intradermal

Intervention Hierarchy (Ancestors)

Injections, SubcutaneousInjectionsDrug Administration RoutesDrug TherapyTherapeutics

Study Officials

  • Chotip Jitudomtham, MD

    Dhurakij Pundit University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chotip Jitudomtham

Study Record Dates

First Submitted

February 28, 2024

First Posted

March 5, 2024

Study Start

February 28, 2024

Primary Completion

March 5, 2024

Study Completion

June 25, 2024

Last Updated

March 5, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share

Locations